Akeso is banking on strengthening its relationship with Sino Biopharmaceuticals to gain a foothold in China’s cancer drug market despite being a latecomer. Photo: Dreamstime/TNS Akeso is banking on strengthening its relationship with Sino Biopharmaceuticals to gain a foothold in China’s cancer drug market despite being a latecomer. Photo: Dreamstime/TNS
Akeso is banking on strengthening its relationship with Sino Biopharmaceuticals to gain a foothold in China’s cancer drug market despite being a latecomer. Photo: Dreamstime/TNS

Chinese cancer drug developer Akeso banks on pharma tie-up in race with rivals amid record-setting Hong Kong IPO

  • Cancer drug developer to seek approval in June for blood cancer drug to catch up with industry rivals in mainland China
  • Akeso IPO said to have locked up a record HK$166.5 billion of funds from retail investors in Hong Kong

Topic |   Pharmaceuticals
Akeso is banking on strengthening its relationship with Sino Biopharmaceuticals to gain a foothold in China’s cancer drug market despite being a latecomer. Photo: Dreamstime/TNS Akeso is banking on strengthening its relationship with Sino Biopharmaceuticals to gain a foothold in China’s cancer drug market despite being a latecomer. Photo: Dreamstime/TNS
Akeso is banking on strengthening its relationship with Sino Biopharmaceuticals to gain a foothold in China’s cancer drug market despite being a latecomer. Photo: Dreamstime/TNS
READ FULL ARTICLE